PAUL HARTMANN S.P.A

Company snapshot

COMMERCIO ALL INGROSSO DI ARTICOLI MEDICALI ED ORTOPEDICI (DAL 21/09/1989)

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for PAUL HARTMANN S.P.A. Not investment advice.

• What is PAUL HARTMANN S.P.A?

  Paul Hartmann Pty is a pharma organization headquartered in AU. Primary therapeutic focus areas include Premature Birth. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO source

• Is PAUL HARTMANN S.P.A publicly traded?

  PAUL HARTMANN S.P.A appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does PAUL HARTMANN S.P.A develop or market?

  We link 1 drug profile(s) where PAUL HARTMANN S.P.A is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/paul-hartmann-pty-ltd#company-drugs.

• What are the latest developments for PAUL HARTMANN S.P.A?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does PAUL HARTMANN S.P.A focus on?

  PAUL HARTMANN S.P.A focuses on Premature Birth based on our analysis of their pipeline programs and drug development activities.